Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: The choice and schedule of fluoropyrimidine matters
Review
Overview
MeSH Major
Antineoplastic Combined Chemotherapy Protocols
Colorectal Neoplasms
Proto-Oncogene Proteins
ras Proteins
abstract
The lack of benefit for cetuximab with capecitabine/bolus 5-FU regimens is unexpected. Cetuximab should only be used with infusional 5-FU regimens in the first-line treatment of K-ras WT colorectal cancer patients. Further study is urgently needed to elucidate the basis of this observation.
